Verona Pharma Announces US FDA Nod of Ohtuvayre To Treat COPD

Verona Pharma plc, reports the US Food and Drug Administration ("FDA") approved Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease (COPD) in grown-up patients. Since more than 20 years ago, Ohtuvayre is the first...

Silo Pharma and AmplifyBio Team up To Advance SPC-15 For Anxiety

Silo Pharma, biopharmaceutical firm focused on in the formation of novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments declared that it has secured a agreement to its its contract research...

EG 427 Bags US FDA Nod To Initiate phase 1b/2a study of Gene Therapy

EG 427, a biotech firm that is leading the development of pinpoint DNA medicines for common neurology ailments using its unique non-replicative HSV-1 vector platform, announces that it gained Investigational New Drug (IND) authorization from the...

Evommune and AprilBio Ink Pact To Commercialize Antibody Drugs

Evommune, Inc., a clinical-stage biotechnology firm based in Palo Alto that is exploring for new ways to treat immune-mediated inflammatory diseases, declared it has forayed into a definitive, worldwide license agreement with AprilBio Co., Ltd...

PharmaEssentia Concludes Patient Enrollment For Phase 2b EXCEED-ET

PharmaEssentia USA Corporation, a worldwide biopharmaceutical trailblazer situated in Taiwan utilizing profound mastery and demonstrated scientific principles to convey new biologics in hematology, oncology and immunology, declared completion of...

Roche's Ocrevus Bags Marketing Approval From European Commission

Roche, a leading Pharmaceutical firm, declared that the European Commission has given marketing authorisation for Ocrevus (ocrelizumab) subcutaneous (SC) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple...

Lillyn and OpenAI Partner To discover Novel Medicines

Eli Lilly and Company has declared a collaboration with OpenAI, which will allow Lilly to use OpenAI's generative AI to develop novel antimicrobials for drug-resistant diseases. Antimicrobial resistance (AMR) is a major danger to public health...

Allecra and Acino Ink Pact for Allecra's Novel Antibiotic Exblifep

Allecra Therapeutics and Acino declared the signing of a licensing agreement in which Acino acquire privileges to popularize Allecra's anti-microbial medication Exblifep (cefepime/enmetazobactam) within the Republic of South Africa and the member...

GSK's Omjjara Secures Japanese Nod For Treatment of Myelofibrosis

GSK plc, a biotechnology company, reported that Japan's Ministry of Health, Labour and Welfare (MHLW) has endorsed Omjjara (momelotinib) for the treatment of myelofibrosis. Omjjara is an oral, once-daily inhibitor of JAK1/JAK2 and the activin A...

Roche Unveils New Analytical Units For Cobas pro Integrated Solutions

Roche, a leading biotechnology firm, declared the availability of its new analytical units, the cobas c 703 and cobas ISE neo, for the cobas pro integrated solutions, in nations accepting the CE mark. The cobas c 703 and cobas ISE neo logical...

© 2024 India Pharma Outlook. All Rights Reserved.